Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Trial Profile

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms AMBER
  • Most Recent Events

    • 09 Nov 2018 According to a TESARO media release, the monotherapy and combination dose-escalation parts of the study are complete.
    • 09 Nov 2018 According to a TESARO media release, additional data from this study are expected in 2019.
    • 09 Nov 2018 According to a TESARO media release, initial data from this study were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top